Back to Search Start Over

AbbVie to acquire Landos Biopharma got $20.42 per share in cash

Source :
The Fly. March 25, 2024
Publication Year :
2024

Abstract

AbbVie (ABBV) and Landos Biopharma (LABP) announced a definitive agreement under which AbbVie will acquire Landos. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
The Fly
Publication Type :
Periodical
Accession number :
edsgcl.787648150